loader2
Partner With Us NRI

Wockhardt Ltd share Price

Company details

168.00
170.20
145.15
282.55
6M Return -30.80%
1Y Return -36.39%
Mkt Cap.(Cr) 2,426.44
Volume 304,186
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 304,186
NSE

Open Free Trading Account Online with ICICIDIRECT

Wockhardt Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Wockhardt Ltd.

Pharmaceuticals company Wockhardt announced Q4FY23 & FY23 results:

  • Q4FY23:
    • The Company recorded a Revenue of Rs 710 crore in Q4FY23 vs Rs 666 crore in Q4FY22, up 7%
    • EBITDA for Q4FY23 is Rs 47 crore as compared to Rs (22) crore in Q4FY22 registering a substantial growth of 314%
    • UK Business stood at Rs 242 crore in Q4FY23 compared to Rs 223 crore in Q3FY23 registering a growth of 8%. UK Business contributed about 36% of Global Revenue.
    • India Business stood at Rs 125 crore in Q4FY23. India's Business contributed 19% of the Global Revenue.
    • Emerging Markets Business of the Company stood at Rs 173 crore in Q4FY23 compared to Rs 148 crore in Q3FY23 registering a growth of 16%. Emerging Markets Business contributed about 25% of the Global Revenue.
    • Irish Business stood at Rs 44 crore in Q4FY23 compared to Rs 40 crore in Q3FY23 showing a growth of 10%.
    • US Business stood at Rs 50 crore in Q4FY23. US Business contributed 7% of the Global Revenue.
  • FY23:
    • UK Business stood at Rs 887 crore in FY23. UK Business contributed about 33% of Global Revenue.
    • India's Business stood at Rs 609 crore in FY23. India's Business contributed 23% of the Global Revenue.
    • Emerging Markets Business of the Company stood at Rs 555 crore in FY23. Emerging Markets Business contributed about 21% of the Global Revenue.
    • Irish Business stood at Rs 158 crore in FY23 compared to Rs 153 crore in FY22, up 4% 
    • US Business stood at Rs 303 crore in FY23. US Business contributed 11% of the Global Revenue.

 

 

Result PDF

View Other Company Results

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Wockhardt Ltd Stocks COMPARISION

DISCOVER MORE

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 3,849.00 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 3,296.96 39,477.59
LAST 3M 15,440.75 59,034.02
LAST 6M 64,524.17 39,054.82
LAST 12M 119,831.70 83,752.26

Wockhardt Ltd Information

Stock PE (TTM)
0
Promoter Holding
59.31%
Book Value
232.7671
ROCE
1.15%
ROE
-3.06%
Description

  • Wockhardt Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 5,314.72 crores, it is incorporated in the 1960s. It has reported consolidated sales of Rs. 764.02 crores in December’2020. The company is also listed in the Bombay Stock Exchange (BSE) with the code 532300 and listed in the National Stock Exchange (NSE) with the code WOCKPHARMA.

    Wockhardt is a global biotechnology and pharmaceuticals company with its headquarters based in Mumbai. Wockhardt is engaged in producing biopharmaceuticals, nutrition products, vaccines, formulations, and active pharmaceuticals ingredients (APIs). The company has various manufacturing plants in India and the USA. Notably, more than half of its revenue is generated in Europe. It has a market presence in many countries around the globe, such as India, the USA, UK, Brazil, Russia, Mexico, Kenya, Ghana, etc. Wockhardt Hospitals, a subsidiary of Wockhardt ltd is a healthcare network of tertiary care and super specialty healthcare services in India. These hospitals offer services in the fields of Cardiology, Orthopedics, Neurology, Gastroenterology, Urology, etc. The promoters of the company own 69.68% of the stake in the company, Foreign Institutional Investors (FII) own 2.73%, Domestic Institutional Investors (DII) own 0.09% of the stake, and others (such as public & retail investors) hold the balance of 27.50%.

    In June 2021, quarterly net revenue was Rs. 278.95 crores, which has increased by approximately 57.08 % from Rs. 177.58 crores for the April-June 2020 quarter. The quarterly net loss in June 2021 was Rs. 48.69 crores, which has seen a sharp decline by nearly 106.35% from a net profit of Rs. 766.39 crores in June 2020. In June 2021, the reported operating profit was at Rs. 199.96 crores, which is also reduced by 78.15% as compared to an operating profit of Rs. 915.08 crores for the quarter ending in June 2020. From Rs. 69.21 in June 2020, the EPS of Wockhardt Ltd has decreased to (Rs. 4.40) per share in June 2021. WOCKPHARMA’s stock closed at Rs. 488.50 on 17th August’2021 (NSE) and has returned -2.36% in the last six months and 49.78% in the previous year.

Read More

No Data Found

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 532300
NSE Code : WOCKPHARMA
Book Closure Date (Month) : Jul/Aug
BSE Group : A
ISIN : INE049B01025

FAQ’s on Wockhardt Ltd Shares

You can buy Wockhardt Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Wockhardt Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 02, 2023 03:59 PM the closing price of Wockhardt Ltd was ₹ 168.40.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jun 02, 2023 03:59 PM, the market cap of Wockhardt Ltd stood at ₹ 2,426.44.

The latest PE ratio of Wockhardt Ltd as of Jun 02, 2023 03:59 PM is 0

The latest PB ratio of Wockhardt Ltd as of Jun 02, 2023 03:59 PM is 1.38

The 52-week high of Wockhardt Ltd is ₹ 282.55 while the 52-week low is ₹ 145.15

Download Our App

market app
market app